Aldeyra price target raised to $28 from $23 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Aldeyra to $28 from $23 and keeps a Buy rating on the shares. With an FDA action dates set for ADX-2191 in primary vitreoretinal lymphoma and reproxalap in dry eye, Aldeyra has become a "unique investment opportunity in SMID-cap biotech," the analyst tells investors in a research note. The firm expects investors will start to pay more attention to the ADX-2191 opportunity and broad potential for RASP modulation across immune-mediated diseases.